Fertility testing in the UK is undergoing a noticeable shift. Rather than navigating multiple appointments, referrals, and long waiting periods, couples are now able to test from home together and attend their first clinic consultation already equipped with key insights.
Sapyen, a fertility diagnostics company working with leading IVF providers such as Avenues, has launched a coordinated at-home testing package. The suite combines male fertility hormone testing, female AMH testing, and laboratory semen analysis into a single, integrated process.
The structure is simple. The male hormone test evaluates key indicators including testosterone, FSH, and LH, while the female AMH test offers an early indication of ovarian reserve. Each of these tests is priced at £69. They can be combined with Sapyen’s laboratory semen analysis, priced at £149, which uses samples collected at home.
What sets this model apart is not the individual tests themselves, but how they are brought together. Couples can now complete a clinically relevant fertility assessment before attending a consultation, allowing discussions to begin with data rather than uncertainty.
This approach has clear implications. Fertility pathways are often delayed due to fragmented testing processes and limited early involvement from male partners. By engaging both individuals from the outset, clinicians are better positioned to move swiftly from diagnosis to decision-making.
The inclusion of male hormone testing is particularly important. Although male factors account for around half of infertility cases, assessments have traditionally focused on sperm quality alone. By combining semen analysis with hormone profiling, the model offers a broader understanding of male reproductive health.
For female patients, AMH testing provides an early indicator that can influence timelines and inform expectations ahead of treatment decisions. Supporting the system is Sapyen’s ability to transport semen samples efficiently to laboratories, removing traditional time limitations while maintaining analytical accuracy.
Clinics can adopt the system with minimal disruption, as results are delivered in standard clinical formats that integrate easily into existing workflows. For patients, the process is more streamlined, reducing delays and simplifying the overall experience.
The outcome is a new starting point for fertility care — one where couples test together, clinicians gain earlier insights, and clearer decisions can be made from the first appointment.
